Table 3.
Groups | SM No | SM Yes | FU (years) median | ET (years) median |
---|---|---|---|---|
No therapy | 209 (95%) | 11 (5%) | 5 (0.1–23) | NA |
HU | 599 (93%) | 42 (7%) | 6 (0.1–32) | 4 (0.1–30) |
ALK | 24 (92%) | 2 (8%) | 12 (1–30) | 8 (0.4–23) |
ALK + HU | 79 (92%) | 7 (8%) | 10 (2–26) | 9 (0.6–24) |
ANA/IFN | 51 (96%) | 2 (4%) | 8 (2–21) | 4 (0.1–20) |
HU, hydroxyurea; ALK, alkylating agents; ANA, anagrelide; IFN, α‐interferon; SM, secondary malignancy; FU, follow‐up; ET, exposure time.